Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Sunscreen Decision Deadlines, Expedited TEAs Proposed

This article was originally published in The Tan Sheet

Executive Summary

The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.

Advertisement

Related Content

Sunscreen TEA Review Deadlines In Limbo In House, Default Approvals Cut
Sunscreen TEA Review Deadlines In Limbo In House, Default Approvals Cut
EWG Seeks Realistic FDA Review Deadlines In Sunscreen Innovation Act
EWG Seeks Realistic FDA Review Deadlines In Sunscreen Innovation Act
Sunscreen Ingredient Legislation Could Ride Wave Of Momentum
Sunscreen Ingredient Legislation Could Ride Wave Of Momentum
Dingell Backs Sunscreen TEA Reform As Sun Sets On His Career
House Pushes FDA To Expedite Sunscreen Ingredient Reviews
FDA Questions Spray Sunscreen Safety, Efficacy And Monograph Status
MHRA on herbals

Topics

Advertisement
UsernamePublicRestriction

Register

PS106807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel